GlassScriptPhysician profile
Irma Kuptel
NPI 1508808999
$3,774.13
in general payments reported to CMS, 2019-2025
35 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $831 · 2021: $1,010 · 2022: $527 · 2023: $14.63 · 2024: $111 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $235.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $735.28 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $290.00 | 2019-2022 | |
| Pfizer INC. | $285.11 | 2019-2025 | |
| Allergan, INC. | $272.01 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.29 | 2019-2022 | |
| Abbvie INC. | $196.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $168.44 | 2019-2022 | |
| Amarin Pharma, INC. | $147.76 | 2019-2022 | |
| Amgen INC. | $146.35 | 2020-2025 | Krystexxa, Otezla, Repatha |
| Ibsa Pharma INC. | $146.29 | 2019-2022 | |
| Astellas Pharma US INC | $93.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $87.59 | 2019-2020 | |
| Janssen Biotech, INC. | $86.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $82.19 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $79.86 | 2019-2021 | |
| Lilly USA, LLC | $77.25 | 2019-2025 | Mounjaro, Zepbound |
| Currax Pharmaceuticals LLC | $73.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.39 | 2020-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $72.06 | 2019-2022 | |
| Almatica Pharma LLC | $51.13 | 2021-2022 | |
| Exact Sciences Corporation | $37.11 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Nestle Healthcare Nutrition INC. | $34.98 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.66 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.11 | 2019 | |
| Bausch Health US, LLC | $24.47 | 2022 | |
| Vivus LLC | $23.16 | 2019-2020 | |
| Dexcom, INC. | $21.88 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $21.58 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.21 | 2020 | |
| Sanofi Pasteur INC. | $14.29 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.75 | 2019 | |
| Phadia US INC. | $13.11 | 2021 | |
| Alfasigma USA, INC. | $12.43 | 2021 | |
| Metuchen Pharmaceuticals | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irma Kuptel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.